Suzhou Ribo Life Science and Ribocure Pharmaceuticals announced the submission of a Phase 2 clinical trial application to the EMA for siRNA-based therapy aimed at coronary artery disease, marking a significant advancement in thromboembolic treatment.

MyOme reveals groundbreaking research integrating genetic and clinical data for improved coronary artery disease risk prediction. Discover the implications today.

Suzhou Ribo Life Science has officially submitted a Phase 2 Clinical Trial for RBD1119, targeting coronary artery disease with innovative siRNA therapies.

Suzhou Ribo Life Science announces positive outcomes from the Phase 2a trial of Vortosiran, the first siRNA therapy targeting FXI in chronic coronary artery disease patients.

Isomab Ltd has released a landmark study reassuring the safety of angiogenic therapies in treating coronary artery disease, targeting innovative treatments and paving the way for future discoveries.

Boston Scientific's FRACTURE IDE trial for the SEISMIQ™ 4CE Coronary Catheter demonstrated significant safety and efficacy in treating severe coronary artery disease, promising for future patient care.

A recent study highlights the connection between long-term exposure to air pollutants and increased coronary artery disease severity, revealing crucial gender differences.

Acarix announces a peer-reviewed study highlighting the CADScor® System's cost-effectiveness, with potential savings of up to $15.3M per 10,000 patients in U.S. emergency departments.